Keros Therapeutics, Inc.(KROS)Earnings, Financials & Key Ratios

KROS•NASDAQ

$11.65

5.1× P/E·Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Rare Disease Biopharma

AboutKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Show more

Revenue$244M+6775.0%
EBITDA$72M+134.4%
Net Income$87M+146.4%
EPS (Diluted)2.30+146.0%
Gross Margin99.38%-0.6%
EBITDA Margin29.55%+100.5%
Operating Margin28.94%+100.5%
Net Margin35.65%+100.7%
ROE19.9%+148.0%

KROS Price & Volume

Keros Therapeutics, Inc. (KROS) stock price & volume — 10-year historical chart

Loading chart...

Episodic Milestone Revenue Masks Clinical Burn Rate

Investment Thesis • Updated 2026Q1

VerdictNeutral

Growth:Mixed

Profitability:Negative

Financial:Healthy

Cash Flow:Burning

Primary Risk:Clinical trial execution risk

Key Thesis Takeaways

Keros Therapeutics remains a high-risk, clinical-stage biotechnology firm whose financial profile is defined by extreme revenue volatility tied to non-recurring milestone payments rather than sustainable commercial operations.
While the company maintains a robust liquidity position with a current ratio of 22.62, the underlying business model is characterized by heavy R&D intensity, consistently exceeding $37M per quarter.
Investors should monitor the sustainability of this funding model, as the $505.5M accumulated deficit underscores the significant capital required to advance the TGF-beta platform toward potential commercialization.

Verdict Logic

while the company holds $281.5M in cash as of 2026Q1, the lack of recurring revenue and the high quarterly R&D burn rate of approximately $16M to $49M suggest significant execution risk for long-term investors.

KROS Growth Metrics

Keros Therapeutics, Inc. (KROS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-84.55%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-2121.49%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-712.5%

Return on Capital

10 Years-35.99%

5 Years-29.66%

3 Years-27.67%

Last Year15.59%

KROS Recent Earnings

Keros Therapeutics, Inc. (KROS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (43%)

Q2 2026Latest

May 14, 2026

Metric

Actual

Est

EPS

$1.21-31.5%

$0.92

Rev

$367,000-81.0%

$2M

Q2 2026

Mar 4, 2026

Metric

Actual

Est

EPS

$0.86-75.5%

$0.49

Rev

$385,000-89.5%

$4M

Q4 2025

Nov 5, 2025

Metric

Actual

Est

EPS

$0.18+83.8%

$1.11

Rev

$14M+289.4%

$4M

Q3 2025

Aug 6, 2025

Metric

Actual

Est

EPS

$0.76+33.3%

$1.14

Rev

$18M+465.9%

$3M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 14, 2026	$1.21vs $0.92-31.5%	$367,000vs $2M-81.0%
Q2 2026	Mar 4, 2026	$0.86vs $0.49-75.5%	$385,000vs $4M-89.5%
Q4 2025	Nov 5, 2025	$0.18vs $1.11+83.8%	$14Mvs $4M+289.4%
Q3 2025	Aug 6, 2025	$0.76vs $1.14+33.3%	$18Mvs $3M+465.9%

Based on last 12 quarters of dataView full earnings history →

Latest KROS News

Recent stock market news and headlines for Keros Therapeutics, Inc. (KROS)

GlobeNewsWire·Jun 25, 2026

Keros Therapeutics Appoints Anne Prener to its Board of Directors

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.

Peers Comparison

Key metrics vs top competitors for Keros Therapeutics, Inc. (KROS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
KROSKeros Therapeutics, Inc.Current	$11.65	$372.78M	5.07	6774.96%	35.65%	19.9%	—
IMVTImmunovant, Inc.	$40.09	$8.23B	-14.47	—	—	-68.16%	—
KRYSKrystal Biotech, Inc.	$368.60	$10.87B	53.89	33.94%	53.92%	19.25%	—
DAWNDay One Biopharmaceuticals, Inc.	$21.53	$2.22B	-20.70	20.6%	-67.85%	-23.43%	—
BEAMBeam Therapeutics Inc.	$37.92	$3.9B	-46.81	120.01%	-49.17%	-5.89%	—
FOLDAmicus Therapeutics, Inc.	$14.49	$4.55B	-164.85	20.05%	-4.27%	-12.02%	—

Compare KROS vs Peers

Keros Therapeutics, Inc. (KROS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for KROS.

Scale Benchmark

vs LLY

Larger-name benchmark to compare KROS against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, KRYS, DAWN, BEAM

KROS SEC Filings & Documents

Keros Therapeutics, Inc. (KROS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 14, 2026·SEC

Material company update

Mar 9, 2026·SEC

Material company update

Mar 4, 2026·SEC

10-K Annual Reports

FY 2026

Mar 4, 2026·SEC

FY 2025

Feb 26, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 14, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when KROS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

KROS Frequently Asked Questions

Keros Therapeutics, Inc. (KROS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Keros Therapeutics, Inc.'s revenue?

Keros Therapeutics, Inc. (KROS) reported $33.2M in revenue for fiscal year 2025. This represents a 232% increase from $10.0M in 2018.

How fast is Keros Therapeutics, Inc. growing?

Keros Therapeutics, Inc. (KROS) grew revenue by 6775.0% over the past year. This is strong growth.

Is KROS profitable?

Keros Therapeutics, Inc. (KROS) reported a net loss of $85.1M for fiscal year 2025.

Dividend & Returns

What is KROS's return on equity?

Keros Therapeutics, Inc. (KROS) has a return on equity (ROE) of 19.9%. This is reasonable for most industries.

What is Keros Therapeutics, Inc.'s free cash flow?

Keros Therapeutics, Inc. (KROS) had negative free cash flow of $58.3M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in KROS back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 14, 2026

$1.21vs $0.92-31.5%

$367,000vs $2M-81.0%

Q2 2026

Mar 4, 2026

$0.86vs $0.49-75.5%

$385,000vs $4M-89.5%

Q4 2025

Nov 5, 2025

$0.18vs $1.11+83.8%

$14Mvs $4M+289.4%

Q3 2025

Aug 6, 2025

$0.76vs $1.14+33.3%

$18Mvs $3M+465.9%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

KROSKeros Therapeutics, Inc.Current

$11.65

$372.78M

5.07

6774.96%

35.65%

19.9%

—

IMVTImmunovant, Inc.

$40.09

$8.23B

-14.47

—

-68.16%

—

KRYSKrystal Biotech, Inc.

$368.60

$10.87B

53.89

33.94%

53.92%

19.25%

—

DAWNDay One Biopharmaceuticals, Inc.

$21.53

$2.22B

-20.70

20.6%

-67.85%

-23.43%

—

BEAMBeam Therapeutics Inc.

$37.92

$3.9B

-46.81

120.01%

-49.17%

-5.89%

—

FOLDAmicus Therapeutics, Inc.

$14.49

$4.55B

-164.85

20.05%

-4.27%

-12.02%

—